Responder analysis to demonstrate the effect of targeting type 2 inflammatory mechanisms with dupilumab across objective and patient‐reported endpoints for patients with severe chronic rhinosinusitis with nasal polyps in the SINUS‐24 and SINUS‐52 studies
Abstrak
1Ghent University, Ghent, Belgium 2Karolinska Institutet, Stockholm, Sweden 3The First Affiliated Hospital, Sun Yatsen University, Guangzhou, China 4AllergyImmunology Division and the Sinus and Allergy Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA 5Personalized Medicine, Asthma & Allergy Humanitas Clinical and Research Center IRCCS, Rozzano, Milan, Italy 6Department of Biomedical Science, Humanitas University, Milan, Italy 7Eastern Virginia Medical School, Norfolk, Virginia, USA 8Department of Otorhinolaryngology, CharitéUniversitätsmedizin Berlin, Berlin, Germany 9Section of Rhinology and Allergy, Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Marburg, PhilippsUniversität Marburg, Marburg, Germany 10Sanofi, Cambridge, Massachusetts, USA 11Sanofi, Reading, UK 12Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA 13Sanofi, Bridgewater, New Jersey, USA
Topik & Kata Kunci
Penulis (16)
C. Bachert
Anju T Peters
E. Heffler
Joseph K. Han
H. Olze
O. Pfaar
C. Chuang
R. Rout
Richa Attre
L. Goga
J. Jacob-Nara
P. Rowe
Y. Deniz
Zhen Chen
S. Kamat
S. Siddiqui
Format Sitasi
Akses Cepat
- Tahun Terbit
- 2022
- Bahasa
- en
- Total Sitasi
- 10×
- Sumber Database
- Semantic Scholar
- DOI
- 10.1111/cea.14051
- Akses
- Open Access ✓